Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|January 10, 2018
Results for Ipilimumab and Nivolumab Following Autologous Stem Cell Transplant in Multiple Myeloma
Author(s)Andrew L. Pecora, MD
Andrew L. Pecora, MD, President of the Physician Services Division and Chief Innovation Officer at Hackensack Meridian Health, discusses preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) as consolidation therapy following autologous stem cell transplant in patients with multiple myeloma and non-Hodkin lymphoma.
Advertisement
Advertisement
Related to this article
Etentamig, a BCMAxCD3 bispecific antibody, was submitted for potential FDA approval based on the phase 3 CERVINO trial in relapsed/refractory multiple myeloma.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
4
Lenvatinib Plus Pembro Remains Frontline Standard in RCC
5